Skip to navigation Skip to main content Skip to footer

Approved Research

Prevention and Remediation of Insulin Multimorbidity in Europe (PRIME)

Principal Investigator: Dr Silke Matura
Approved Research ID: 62644
Approval date: May 4th 2021

Lay summary

The 5-year long project called 'PRIME' (Prevention and Remediation of Insulin Multimorbidity in Europe) aims to unravel how brain disorders throughout life can be traced to alterations in insulin signalling and how this relates to the somatic diseases type 2 diabetes and obesity. Insulin-related illnesses (insulinopathies) present a major health, societal, and economic burden. The known somatic insulinopathies are often long-term, chronic illnesses. So far, there is hardly any knowledge about brain-based insulinopathies. Medical efforts are mainly or only devoted to the management of somatic insulinopathies, with little attention to additional effects of altered insulin signalling on the brain.

PRIME will break new ground in addressing this problem, starting from the hypothesis that altered insulin signalling not only has effects on somatic illnesses but also on neurodevelopmental and neurodegenerative disorders, especially those linked to cognitive inflexibility. By probing the causal mechanisms linking somatic and brain-based insulin-related illnesses, PRIME's multidisciplinary team will work to extend our understanding of insulin-related effects across the lifespan. The researchers also hope to develop tools for better diagnosis, improved clinical treatment, and potentially prevention of comorbid insulinopathies. PRIME will work with large population data sets to identify and validate new insulinopathies and subsequently use highly interdisciplinary approaches to study insulin communication between body and brain from molecule to cell, brain, cognition, and behaviour. In addition to increased mechanistic understanding, the PRIME project aims to outline new directions for research and clinical care.